Mark van Heijl, Jikke M T Omloo, Mark I van Berge Henegouwen, Olivier R C Busch, Hugo W Tilanus, Patrick M M Bossuyt, Otto S Hoekstra, Jaap Stoker, Maarten C C M Hulshof, Ate van der Gaast, Grard A P Nieuwenhuijzen, Han J Bonenkamp, John Th M Plukker, Ernst J Spillenaar Bilgen, Fibo J W Ten Kate, Ronald Boellaard, Jan Pruim, Gerrit W Sloof, J Jan B van Lanschot
BACKGROUND: Surgical resection is the preferred treatment of potentially curable esophageal cancer. To improve long term patient outcome, many institutes apply neoadjuvant chemoradiotherapy. In a large proportion of patients no response to chemoradiotherapy is achieved. These patients suffer from toxic and ineffective neoadjuvant treatment, while appropriate surgical therapy is delayed. For this reason a diagnostic test that allows for accurate prediction of tumor response early during chemoradiotherapy is of crucial importance...
July 31, 2008: BMC Medical Physics